trial

Translational Investigation of the Glutamatergic and GABAergic System in Schizophrenia

NCTId NCT04655235
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Recruiting
Enrollment 600 (estimated)
Sponsored by RWTH Aachen University
Primary completion 2028-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
600 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2021-10-01
Primary completion
2028-12
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
Genotyping

Sponsors

RWTH Aachen UniversityLead Sponsor

Investigators

1
Arnim Gaebler, M.D.Principal Investigator

Sites

3 total
Aachen, GermanyGangelt, GermanyAachen, Germany

Facts & assertions

4 sourced
Enrollment
600
Phase
NA
Primary Completion Date
2028-12
Status
RECRUITING
relationships
The graph out of here
drug
Genotyping
drug
lead_sponsor
RWTH Aachen University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Arnim Gaebler, M.D.
person